Q-omics provides the consensus-scored ZBTB47 profile across patient tissues and cancer cell-line models. ZBTB47 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ZBTB47 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, ZBTB47 RNA expression shows 20,521 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CESC, BLCA, and GBM as cancer lineages where ZBTB47 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB47 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB47 survival associations across molecular data types. ZBTB47 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB47 RNA expression–survival associations across cancer types. High ZBTB47 expression shows unfavorable associations in CESC, BLCA and LUSC, but favorable associations in UVM, LGG and GBM. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for ZBTB47 RNA expression.
This table summarizes ZBTB47 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB47. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB47 shows lower tumor expression in BLCA, THCA, KIRC and LUAD and higher tumor expression in KICH and LIHC. The BLCA box plot shows higher ZBTB47 RNA expression in normal versus tumor tissue (log2 FC = −2.110, t-test p < 0.001).
This table shows molecular features associated with ZBTB47 in patient tissues and cancer cell lines. In patient samples, ZBTB47 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB47 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
